Shares of G1 Therapeutics Inc. (NASDAQ:GTHX) traded today at $69.36, eclipsing its 52-week high. This new high was reached on above average trading volume as 35.4 million shares traded hands, while the average 30-day volume is approximately 839,000 shares.
G1 Therapeutics Inc. has overhead space with shares priced $8.09, or 0.4% below the average consensus analyst price target of $8.12.
In the past 52 weeks, shares of G1 Therapeutics Inc. have traded between a low of $7.28 and a high of $69.36 and is now at $8.09, which is 11% above that low price.
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer such as cell lung cancer and breast cancer and designs them to combine – and enhance – the anti-tumor activity of current therapies.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer